1. Marta, Żebrowska-Nawrocka, Agnieszka, Wosiak, Jacek, Pietrzak, Sałagacka-Kubiak, Aleksandra, Balcerczak, Ewa. 2020. NFKB2 gene expression in patients with peptic ulcer diseases and gastric cancer. In Molecular biology reports, 47, 2015-2021. doi:10.1007/s11033-020-05299-5. https://pubmed.ncbi.nlm.nih.gov/32056043/
2. Jabbari Moghadam, Yalda, Asadi, Mohammad Reza, Abbaszadeh, Vahdat, Akbari Dilmaghnai, Nader, Rezazadeh, Maryam. 2023. Analysis of NFKB1 and NFKB2 gene expression in the blood of patients with sudden sensorineural hearing loss. In International journal of pediatric otorhinolaryngology, 166, 111470. doi:10.1016/j.ijporl.2023.111470. https://pubmed.ncbi.nlm.nih.gov/36773447/
3. Fathi, Nazanin, Nirouei, Matineh, Salimian Rizi, Zahra, Almasi-Hashiani, Amir, Rezaei, Nima. 2024. Clinical, Immunological, and Genetic Features in Patients with NFKB1 and NFKB2 Mutations: a Systematic Review. In Journal of clinical immunology, 44, 160. doi:10.1007/s10875-024-01763-0. https://pubmed.ncbi.nlm.nih.gov/38990428/
4. Mueller, Sebastian, Engleitner, Thomas, Maresch, Roman, Saur, Dieter, Rad, Roland. 2018. Evolutionary routes and KRAS dosage define pancreatic cancer phenotypes. In Nature, 554, 62-68. doi:10.1038/nature25459. https://pubmed.ncbi.nlm.nih.gov/29364867/
5. Deng, Guangtong, Zeng, Furong, Su, Juan, Chen, Xiang, Yin, Mingzhu. 2020. BET inhibitor suppresses melanoma progression via the noncanonical NF-κB/SPP1 pathway. In Theranostics, 10, 11428-11443. doi:10.7150/thno.47432. https://pubmed.ncbi.nlm.nih.gov/33052224/
6. Xu, Chang, Huang, Kie Kyon, Law, Jia Hao, So, Jimmy Bok-Yan, Tan, Patrick. 2023. Comprehensive molecular phenotyping of ARID1A-deficient gastric cancer reveals pervasive epigenomic reprogramming and therapeutic opportunities. In Gut, 72, 1651-1663. doi:10.1136/gutjnl-2022-328332. https://pubmed.ncbi.nlm.nih.gov/36918265/
智鼠故事 
